PYC and FDA seeing eye-to-eye – The Cairns Post
PYC and FDA seeing eye-to-eye The Cairns Post Source link credite
Ovarian Cancer
New blood test could detect ovarian cancer early, improve treatment
High-grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer. It is also the most lethal form, in part because clinicians do not have effective ways to screen women for it during the cancer’s early stages, when it’s easiest to treat. For patients with a pelvic mass (an abnormal lump or growth … Read more
Women have widespread confusion and misconceptions about ovarian cancer screening
Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today revealed new nationwide survey results indicating widespread confusion and misconceptions about ovarian cancer screening among a majority of women. The Myriad Genetics Cancer Risk survey shows that nearly three out of four women (71%) falsely believe annual pap smears include testing for ovarian … Read more
Study identifies potential target for reversing drug resistance in ovarian cancer
For the 314,000 people diagnosed with ovarian cancer each year, hope often comes in the form of platinum-based drugs such as cisplatin. Cisplatin causes the death of quick-dividing tumour cells, so it is a potent first-line defence in the treatment of the often fatal disease. However, over half of ovarian cancer patients develop recurrence and … Read more
Ovarian cancer patients enrolled in first-in-human trial of CAR T cell therapy
Recently published preclinical data by City of Hope scientists shows the immunotherapy is effective. Advanced ovarian cancer patients are now being enrolled in a Phase 1 first-in-human trial. There are currently few effective treatment options for patients with recurrent ovarian cancer and other solid tumors, but City of Hope researchers are trying to change that. … Read more